Special Issue

The Present and Future of Personalized Medicine in Oncology

Message from the Guest Editor

The implementation of precision medicine has tremendously increased the need for molecular characterization of tumours, as well as the amount of genetic data. Its complexity has brought to the development of so-called Molecular Tumour Boards, where clinical and genomic/transcriptomic data are discussed in order to derive relevant prognostic and predictive decisions, possibly leading to a better cancer treatment. Functional validation of a conspicuous number of molecular alterations is lacking, while it could lead to a significant rescue of patients to molecularly guided treatment. Key open questions also regard the implementation of a precision medicine approach in immunotherapy and the need for re-biopsy of progressive disease, looking for the emergence of resistance druggable mutations. This Special Issue of the *Journal of Personalized Medicine* aims to delineate present and future perspectives of precision medicine in oncology, from clinical data in real life situations to newly introduced biomarkers and emerging technologies such as liquid biopsy and patient-derived models.

Guest Editor

Dr. Federica Papaccio

Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana" , University of Salerno, 84081 Baronissi, Italy

Deadline for manuscript submissions

closed (10 October 2022)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).